NIROGACESTAT HYDROBROMIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H41F2N5O.2BrH
Molecular Weight	651.468
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Br.Br.CCC[C@H](N[C@H]1CCC2=C(C1)C(F)=CC(F)=C2)C(=O)NC3=CN(C=N3)C(C)(C)CNCC(C)(C)C

InChI

InChIKey=LXEYYZYDWLAIPW-KBVFCZPLSA-N

InChI=1S/C27H41F2N5O.2BrH/c1-7-8-23(32-20-10-9-18-11-19(28)12-22(29)21(18)13-20)25(35)33-24-14-34(17-31-24)27(5,6)16-30-15-26(2,3)4;;/h11-12,14,17,20,23,30,32H,7-10,13,15-16H2,1-6H3,(H,33,35);2*1H/t20-,23-;;/m0../s1

HIDE SMILES / InChI

Molecular Formula	C27H41F2N5O
Molecular Weight	489.6441
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	BrH
Molecular Weight	80.912
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://adisinsight.springer.com/drugs/800025563
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20363853 | https://www.ncbi.nlm.nih.gov/pubmed/24919951 | https://www.ncbi.nlm.nih.gov/pubmed/21269827

Nirogacestat (PF-3084014) is a tetralin imidazole gamma-secretase inhibitor. Gamma-secretase, a proteolytic enzyme complex, mediates processing of several integral membrane proteins including amyloid precursor protein and Notch. This compound can inhibit both Notch-related pathway in neoplasia and reduces amyloid-β production. Nirogacestat (PF-3084014) is under development by Pfizer for the treatment of cancer.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Gamma-secretase 21 Target ID: CHEMBL2094135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20363853	Inhibitor 8504		1.2 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Aggressive Fibromatosis 2 Sources: http://adisinsight.springer.com/drugs/800025563	Primary	Phase II 1147	Unknown Approved Use Unknown
Pancreatic cancer 98 Sources: http://adisinsight.springer.com/drugs/800025563	Primary	Phase II 1147	Unknown Approved Use Unknown
Breast cancer 432 Sources: http://adisinsight.springer.com/drugs/800025563	Primary	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
963 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27906684	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:		NIROGACESTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
330 mg 2 times / day multiple, oral Highest studied dose Dose: 330 mg, 2 times / day Route: oral Route: multiple Dose: 330 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25231399	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25231399	DLT: Skin rash... Disc. AE: Palpitations, Oropharyngeal pain... Dose limiting toxicities: Skin rash (grade 3, 50%) AEs leading to discontinuation/dose reduction: Palpitations (grade 1, 50%) Oropharyngeal pain (grade 1, 50%) Sources: https://pubmed.ncbi.nlm.nih.gov/25231399
220 mg 2 times / day multiple, oral MTD Dose: 220 mg, 2 times / day Route: oral Route: multiple Dose: 220 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25231399	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25231399	DLT: Diarrhea... Dose limiting toxicities: Diarrhea (grade 3, 16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/25231399
150 mg 2 times / day multiple, oral Studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28350521	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/28350521	Disc. AE: Nausea, Diarrhea... AEs leading to discontinuation/dose reduction: Nausea (grade 2, 5.9%) Diarrhea (grade 2, 5.9%) Allergic urticaria (5.9%) Maculopapular rash (grade 2, 5.9%) Sources: https://pubmed.ncbi.nlm.nih.gov/28350521

AEs

AE	Significance	Dose	Population
Oropharyngeal pain	grade 1, 50% Disc. AE	330 mg 2 times / day multiple, oral Highest studied dose Dose: 330 mg, 2 times / day Route: oral Route: multiple Dose: 330 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25231399	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25231399
Palpitations	grade 1, 50% Disc. AE	330 mg 2 times / day multiple, oral Highest studied dose Dose: 330 mg, 2 times / day Route: oral Route: multiple Dose: 330 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25231399	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25231399
Skin rash	grade 3, 50% DLT	330 mg 2 times / day multiple, oral Highest studied dose Dose: 330 mg, 2 times / day Route: oral Route: multiple Dose: 330 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25231399	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25231399
Diarrhea	grade 3, 16.7% DLT	220 mg 2 times / day multiple, oral MTD Dose: 220 mg, 2 times / day Route: oral Route: multiple Dose: 220 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25231399	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25231399
Allergic urticaria	5.9% Disc. AE	150 mg 2 times / day multiple, oral Studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28350521	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/28350521
Diarrhea	grade 2, 5.9% Disc. AE	150 mg 2 times / day multiple, oral Studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28350521	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/28350521
Maculopapular rash	grade 2, 5.9% Disc. AE	150 mg 2 times / day multiple, oral Studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28350521	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/28350521
Nausea	grade 2, 5.9% Disc. AE	150 mg 2 times / day multiple, oral Studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28350521	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/28350521

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087 substrate 1946 inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C19 2057 CYP3A 227 P-gp 1741	CYPs 33 rP-gp 2

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=363678166	inconclusive [IC50 8.1995 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://www.clinicaltrials.gov/ProvidedDocs/51/NCT01981551/Prot_SAP_000.pdf#page=14 Page: 14.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.clinicaltrials.gov/ProvidedDocs/51/NCT01981551/Prot_SAP_000.pdf#page=14 Page: 14.0	weak [IC50 13.5 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.clinicaltrials.gov/ProvidedDocs/51/NCT01981551/Prot_SAP_000.pdf#page=14 Page: 14.0	weak [IC50 18.5 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.clinicaltrials.gov/ProvidedDocs/51/NCT01981551/Prot_SAP_000.pdf#page=14 Page: 14.0	weak [IC50 20.3 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.clinicaltrials.gov/ProvidedDocs/51/NCT01981551/Prot_SAP_000.pdf#page=14 Page: 14.0	weak [Ki 2.2 uM]
CYP3A 317	inhibitor 4027 Sources: https://www.clinicaltrials.gov/ProvidedDocs/51/NCT01981551/Prot_SAP_000.pdf#page=14 Page: 14.0	yes [IC50 4.6 uM]	yes (co-administration study) Comment: Increased midazolam AUCinf and Cmax by 58.9% and 30.7% Sources: https://www.clinicaltrials.gov/ProvidedDocs/51/NCT01981551/Prot_SAP_000.pdf#page=14 Page: 14.0
CYP3A4 2633	inducer 1966 Sources: https://www.clinicaltrials.gov/ProvidedDocs/51/NCT01981551/Prot_SAP_000.pdf#page=14 Page: 14.0	yes
P-gp 1932	supressor 160 Sources: https://pubmed.ncbi.nlm.nih.gov/26202948/	yes

Drug as victim

Target	Modality	Activity
CYPs 33	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23427934/	likely
rP-gp 2	substrate 4014 Sources: https://www.clinicaltrials.gov/ProvidedDocs/51/NCT01981551/Prot_SAP_000.pdf#page=14 Page: 14.0	no
CYP3A4 1946	substrate 4014 Sources: https://www.clinicaltrials.gov/ProvidedDocs/51/NCT01981551/Prot_SAP_000.pdf#page=10 Page: 10.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.clinicaltrials.gov/ProvidedDocs/51/NCT01981551/Prot_SAP_000.pdf#page=11 Page: 11.0

PubMed

Title	Date	PubMed
Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.	2010 Jul	20363853
Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.	2010 Jun	20530712
Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model.	2013 Aug 6	23868008
Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.	2014 Aug	24664981
Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors.	2015 Nov 15	26349011

Sample Use Guides

In Vivo Use Guide

Dosage of Nirogacestat (PF-3084014) in phase II trial in adults with desmoid tumors/aggressive fibromatosis: orally at 150 mg twice a day in 21-day cycles

Route of Administration: Oral

In Vitro Use Guide

Nirogacestat (PF-3084014) can block Nicastrin/Notch4 axis and reverse epithelial to mesenchymal transition process in in MCF7 breast cancer cells.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 01:00:32 GMT 2025` Edited by `admin` on `Wed Apr 02 01:00:32 GMT 2025`
Record UNII	9T1XY6L45Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NIROGACESTAT HYDROBROMIDE

Official Name

English

OGSIVEO

Preferred Name

English

(2S)-2-{[(2S)-6,8-Difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino}-N-(1-{1-[(2,2-dimethylpropyl)amino]-2-methylpropan-2-yl}-1H-imidazol-4-yl)pentanamide dihydrobromide

Systematic Name

English

PENTANAMIDE, 2-(((2S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRO-2-NAPHTHALENYL)AMINO)-N-(1-(2-((2,2-DIMETHYLPROPYL)AMINO)-1,1-DIMETHYLETHYL)-1H-IMIDAZOL-4-YL)-, HYDROBROMIDE (1:2), (2S)-

Systematic Name

English

Nirogacestat hydrobromide [WHO-DD]

Common Name

English

PF-03084014-04

Code

English

NIROGACESTAT DIHYDROBROMIDE

Common Name

English

NIROGACESTAT HYDROBROMIDE [USAN]

Common Name

English

Code System Code Type Description

PUBCHEM

121513889